The 2026 American Society of Clinical Oncology (ASCO) annual meeting is quickly approaching. From May 29 through June 2, in Chicago, Illinois, the 2026 ASCO Annual Meeting features groundbreaking research presentations, networking opportunities, and more. For five days, attendees can experience sessions featuring global leaders in oncology discussing the key developments shaping the future of the field.

Today, we are previewing sessions on multiple myeloma topics that attendees can look forward to experiencing. Dates and times are accurate as of April 28, 2026. For a complete look at the following sessions, along with all the other sessions currently scheduled, visit the official 2026 ASCO Annual Meeting program guide.

Multiple Myeloma Sessions at the 2026 ASCO Annual Meeting

Friday, May 29

  • Care Delivery/Models of Care
    • 2:45 PM – 4:15 PM
    • Description: During this rapid oral abstract session, one of the scheduled presentations is, Randomized Controlled Trial of a Psychosocial Digital Application (THRIVE-MM) for Patients Living with Multiple Myeloma.
  • Hematologic Malignancies – Plasma Cell Dyscrasia
    • 2:45 PM – 5:45 PM
    • Description: This oral abstract session features presentations including, Intercepting Plasma Cell Disorders: From Smoldering Multiple Myeloma to Amyloid Light-Chain Amyloidosis, Raising the Bar in Newly Diagnosed Multiple Myeloma: Depth, Duration, and Risk, and more.

Saturday, May 30

  • Care Delivery/Models of Care
    • 9:00 AM – 12:00 PM
    • Description:  During this poster session, one of the posters featured is Transportation Insecurity and RBC Transfusion Burden in Multiple Myeloma and Related Plasma Cell Disorders in New Mexico: A CRIIS Statewide Analysis (2013-2019).
  • Industry Expert Theater: Evolving Needs in RMM and Understanding Emerging CELMoD Research
    • 9:30 AM – 10:30 AM
    • Description: This industry expert theater sessions focuses on the evolving needs regarding relapsed/refractory MM and emerging research focusing on Cereblon E3 Ligase modulation.
  • Developmental Therapeutics – Immunotherapy
    • 1:30 PM – 4:30 PM
    • Description: During this poster session, one of the posters featured is Anitocabtagene Autoleucel (anito-cel) Clinical Trial Manufacturing Experience in Patients with Relapsed/Refractory or Newly Diagnosed Multiple Myeloma.
  • Symptom Science and Palliative Care
    • 1:30 PM – 4:30 PM
    • Description: During this poster session, one of the posters featured is Early Outpatient Palliative Care for Patients with Multiple Myeloma: A Randomized Pilot Study.

Sunday, May 31

  • Smoldering Multiple Myeloma: To Treat or Not to Treat
    • 8:00 AM – 9:15 AM
    • Description: This education session has two presentations on multiple myeloma: Con: Risk Versus Benefit – Treating Smoldering Multiple Myeloma in Frail and Older Patients; and Smoldering Multiple Myeloma: Takeaways and Further Considerations.
  • Hematologic Malignancies – Plasma Cell Dyscrasia
    • 9:45 AM – 11:15 AM
    • Description: This rapid oral abstract session features topics that include clinical trial updates on isatuximab plus pomalidomide-dexamethosone in relapsed/refractory multiple myeloma, daratumab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnoses multiple myeloma, and more.
  • Industry Expert Theater: A Treatment Option for Patients with Multiple Myeloma
    • 4:15 PM – 5:15 PM
    • Description: No specific information provided regarding presentation focus.

Monday, June 1

  • High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy
    • 8:00 AM – 9:15 AM
    • Description: This education session will discuss a modern framework for defining high-risk myeloma, frontline therapy in high-risk myeloma, and more.
  • Quality Care/Health Services Research
    • 9:00 AM – 12:00 PM
    • Description: This poster session features topics including cost-effectiveness analysis of teclistamab plus daratumumab in relapsed or refractory multiple myeloma, overall survival of Black patients with newly diagnosed multiple myeloma in the era of triplet and quadruplet therapies, and more.
  • Hematologic Malignancies – Plasma Cell Dyscrasia
    • 9:00 AM – 12:00 PM
    • Description: This poster session features topics including clinical outcomes following CAR T-cell therapy in relapsed or refractory multiple myeloma patients with baseline renal dysfunction, trends in frontline treatment patterns for multiple myeloma among US veterans, and more.

Sign up for alerts and stay informed on the latest clinical guidelines and guideline updates.